title: A randomized controlled trial of levofloxacin, terazosin, and combination therapy in patients with category III chronic prostatitis/chronic pelvic pain syndrome.
abstract: OBJECTIVE
  To explore the efficacy of levofloxacin, terazosin, and their combination in patients with category III chronic prostatitis/chronic pelvic pain syndrome (CP/CPPS).
  
  
  METHODS
  A total of 115 patients with category III CP/CPPS receiving 6-week therapy were randomly divided into the levofloxacin group (n = 38), terazosin group (n = 38), and combination group (n = 39). The primary endpoint was the response rate (i.e., the change from baseline) in the total and domain scores of the National Institutes of Health Chronic Prostatitis Symptom Index (NIH-CPSI). Secondary endpoints were expressed as prostatic secretion-white blood cell (EPS-WBC) and International Index of Erectile Function-5 (IIEF-5).
  
  
  RESULTS
  After 6 weeks, the response rate of NIH-CPSI scores was 45.1, 22.4, and 50.0 % in the levofloxacin group, terazosin group, and combination group, respectively. Furthermore, no significant difference in NIH-CPSI scores was observed between IIIA and IIIB patients in each arm. Levofloxacin alone or levofloxacin plus terazosin could significantly reduce EPS-WBC counts compared with terazosin alone. Finally, no significant difference was found between the three arms in terms of IIEF-5 scores.
  
  
  CONCLUSIONS
  A 6-week short-term treatment of levofloxacin or levofloxacin plus terazosin was more effective than terazosin alone in patients with category III CP/CPPS. Furthermore, levofloxacin treatment was not different from levofloxacin plus terazosin treatment in terms of treatment effect.
authors.affiliation: Department of Urology, Qilu Hospital, Shandong University, No. 107 Wenhua Xi Road, Jinan, 250000, Shandong, China.|Department of Urology, Affiliated Hospital of Binzhou Medical University, Binzhou, 256603, China.
authors.forename: Jianxin
authors.initials: J
authors.lastname: Wang
authors.affiliation: Department of Urology, Affiliated Hospital of Binzhou Medical University, Binzhou, 256603, China.
authors.forename: Dongliang
authors.initials: D
authors.lastname: Yan
authors.affiliation: Department of Obstetrics and Gynecology, Affiliated Hospital of Binzhou Medical University, Binzhou, 256603, China.
authors.forename: Kuixiang
authors.initials: K
authors.lastname: Liang
authors.affiliation: Department of Urology, Qilu Hospital, Shandong University, No. 107 Wenhua Xi Road, Jinan, 250000, Shandong, China. zg9800@163.com.
authors.forename: Zhonghua
authors.initials: Z
authors.lastname: Xu
mesh_terms: D000284:Administration, Oral; D000328:Adult; D000900:Anti-Bacterial Agents / Q000008:administration & dosage / Q000627:therapeutic use*; D002908:Chronic Disease; D004359:Drug Therapy, Combination; D006801:Humans; D064704:Levofloxacin / Q000008:administration & dosage / Q000627:therapeutic use*; D008297:Male; D017699:Pelvic Pain / Q000188:drug therapy*; D011224:Prazosin / Q000008:administration & dosage / Q000031:analogs & derivatives* / Q000627:therapeutic use; D011446:Prospective Studies; D011472:Prostatitis / Q000188:drug therapy*; D013577:Syndrome; D016896:Treatment Outcome; D064804:Urological Agents / Q000008:administration & dosage / Q000627:therapeutic use*
chemical_list: D000900:Anti-Bacterial Agents; D064804:Urological Agents; D064704:Levofloxacin; C041226:Terazosin; D011224:Prazosin
keywords: Levofloxacin; Prostatitis; Terazosin; Treatment